MAP2 and Alzheimer disease: In the present study we found that at 3 months of age, before the start of P021 treatment, there were dendritic and synaptic deficits as seen by the decrease in the levels of MAP2, synaptophysin, PSD-95, and NR1 in 3 × Tg-AD mice.